Welcome to our dedicated page for Insulet SEC filings (Ticker: PODD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Insulet Corporation (NASDAQ: PODD) SEC filings, offering a structured view of the company’s regulatory disclosures as a NASDAQ-listed medical device manufacturer. Insulet develops the Omnipod tubeless insulin pump platform and the Omnipod 5 Automated Insulin Delivery System, and its filings help investors understand how this business is governed, financed, and overseen.
Through Forms 10-K and 10-Q, Insulet reports audited and interim financial statements, risk factors, and management’s discussion of its Omnipod product platform, manufacturing operations, and growth strategy in automated insulin delivery and related drug delivery applications. Current reports on Form 8-K disclose material events such as quarterly financial results, amendments to incentive and severance plans, executive leadership transitions, and appointments to the board of directors and committees.
Investors can also review proxy statements for details on executive and director compensation, governance structures, and shareholder matters, as well as any registration statements related to securities offerings. For monitoring insider activity, Forms 3, 4, and 5 report beneficial ownership and changes in holdings by Insulet’s officers, directors, and other insiders, which some investors use to gauge management’s alignment with shareholders.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly identify important changes in financial performance, risk disclosures, compensation arrangements, or governance. Real-time updates from the SEC’s EDGAR system ensure that new Insulet filings, including 10-Ks, 10-Qs, 8-Ks, and Form 4 insider transaction reports, appear promptly, while AI-generated explanations make complex regulatory language more accessible to a broad range of investors and researchers.
Insulet Corp Group VP, CAO and Controller Lauren Budden reported routine equity compensation transactions. She received a grant of 611 shares of common stock and an option for 1,591 shares, both at a grant price of $0.00 per share, reflecting stock-based awards rather than open‑market activity.
To cover taxes on vested restricted stock units, 55 shares of common stock were withheld at a price of $248.12 per share, characterized as a tax-withholding disposition. Following these transactions, she directly owned 8,744 common shares and held an option for 1,591 shares, with vesting and exercisability occurring in installments over several years.
INSULET CORP senior vice president and general counsel John W. Kapples reported routine equity compensation and related tax withholding transactions. On February 24, he received an annual grant of 1,885 shares of common stock as restricted stock units that vest in three equal installments and settle one-for-one in common shares. He also received an annual non-qualified stock option award for 4,907 shares, which becomes exercisable in four equal installments over four years. On February 25, 263 shares of common stock were withheld at a price of $248.12 per share to cover tax obligations from vesting RSUs, rather than sold in the open market. After these transactions, he directly held 28,119 shares of common stock and 4,907 stock options.
Insulet Corp EVP and COO Benjamin Eric reported a mix of equity awards and share withholding transactions. He received a grant of 3,822 shares of common stock as an annual restricted stock unit award, which will vest in three equal installments on the first, second, and third anniversaries of the grant date. He was also granted 9,946 non-qualified stock options that become exercisable in four equal installments on each of the first four anniversaries of the grant date.
In a separate transaction, 395 shares of common stock were withheld at a price of $248.12 per share to cover tax obligations arising from RSU vesting, reducing his directly held common stock to 24,512 shares after the withholding.
Insulet Corp reported equity awards to senior executive Lisa Blair Davis, the SVP and Chief HR Officer. She received an annual grant of 5,570 employee stock options with an exercise schedule vesting in substantially equal installments over four years from the grant date of February 24, 2026.
On the same date, she was also granted 2,140 restricted stock units (RSUs), which vest in substantially equal installments over three years and settle into common shares on a one-for-one basis. After these grants, she directly owns 4,617 shares of common stock.
INSULET CORP executive Flavia Pease received new equity awards. On the reported date, the EVP & CFO was granted 3,822 shares of common stock and an employee stock option for 9,946 shares at an exercise price of $0.0000 per share.
The 3,822-share grant is an annual restricted stock unit award that vests in substantially equal installments on each of the first, second and third anniversaries of the grant date and settles one-for-one in common stock. The 9,946-share non-qualified stock option becomes exercisable in substantially equal installments on each of the first, second, third and fourth anniversaries of the grant date.
INSULET CORP President and CEO Ashley McEvoy received new equity awards. On February 24, 2026, McEvoy was granted an option to buy 26,143 shares of common stock at an exercise price of $0.00 per share and an award of 10,046 restricted stock units.
The option award becomes exercisable in substantially equal installments on each of the first, second, third and fourth anniversaries of the grant date. The restricted stock units vest in substantially equal installments on each of the first, second and third anniversaries and are settled one-for-one in common shares. Following these awards, McEvoy directly holds 23,962 common shares, with an additional 4 shares held indirectly through a trust.
INSULET CORP director-related trust buys additional shares. On February 25, 2026, a trust associated with director Michael R. Minogue purchased 2,030 shares of Insulet common stock in open-market transactions at a weighted average price of $246.23 per share. After this, the trust held 17,483 shares indirectly, while Minogue also held 778 shares directly.
Insulet Corporation is amending a prior report to confirm that Grant Thornton LLP has completed its audit of the company’s consolidated financial statements for the fiscal year ended December 31, 2025 and has now been dismissed as independent auditor. PricewaterhouseCoopers LLP was previously selected as Insulet’s independent registered public accounting firm for the fiscal year ending December 31, 2026, and that appointment did not affect Grant Thornton’s 2025 engagement.
Grant Thornton’s reports on the company’s 2025 and 2024 financial statements contained no adverse opinions, disclaimers of opinion, or qualifications as to uncertainty, audit scope, or accounting principles. The company states there were no disagreements or reportable events with Grant Thornton through February 18, 2026, and that it did not consult PwC on specific accounting matters, potential audit opinions, disagreements, or reportable events during 2024, 2025, or the subsequent interim period.
Insulet Corp President and CEO Ashley McEvoy reported an open-market purchase of 4,300 shares of common stock on February 20, 2026 at a weighted average price of $239.35 per share. After this transaction, McEvoy directly owned 13,916 common shares, with an additional 4 shares held indirectly by a trust.
The filing notes that these 4,300 shares were bought in multiple trades at prices ranging from $238.55 to $241.56, with specified weighted average prices for each price band.
Insulet Corporation filed its annual report describing how it develops and sells the tubeless Omnipod insulin delivery platform for people with insulin‑dependent diabetes. The company highlights Omnipod 5’s automated insulin delivery, broad CGM integrations, and smartphone control, along with expansion into insulin‑requiring type 2 diabetes and 25 countries.
Insulet reports heavy reliance on Omnipod products and intermediary distributors, ongoing investments in new algorithms and next‑generation systems, and a global manufacturing footprint in the U.S., Malaysia, China, and a planned facility in Costa Rica. As of December 31, 2025, the company had about 5,400 employees and extensive patent protection through 2047, while outlining detailed regulatory, reimbursement, competition, and supply‑chain risks.